Everett, WA – October 27, 2015 – SNBL USA, Ltd., is pleased to announce that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (DHHS). This Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSO100201500006I), with anticipated issuance of fixed-price and cost reimbursement type task orders, was issued to support the development of chemical, radiological, and nuclear (CRN) countermeasures, enabling participating nonclinical laboratories to assist in the animal model development of medical countermeasures and/or supportive reagents and assays for regulatory acceptance in the U.S. “SNBL USA is honored to work with BARDA on this contract, which reflects the government’s commitment to enhancing collaborative partnerships to achieve a state of readiness for public health emergencies,” said Dr. Koichiro Fukuzaki, SNBL USA CEO. “We are confident that our fully-licensed facilities, Good Laboratory Practice (GLP) experience, and knowledgeable scientific leadership will be a unique scientific resource for BARDA’s programs and research initiatives.”
The development of animal models is a key element in the successful development of medical countermeasures (MCMs) for CRN threats, particularly since efficacy of products directed against most of these threats cannot be verified using clinical studies. Dr. Ronald Manning, SNBL USA Senior Director for Model Development comments, “It is most important that the animal models we develop translate to people; a lot of work remains to be done in this area. SNBL USA is committed to the successful development of well-characterized animal models.”
For additional information regarding SNBL services and capabilities, contact us at +1.425.322.1950 or firstname.lastname@example.org.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., and recognized as a leader in conducting GLP-compliant nonclinical toxicology studies, SNBL USA offers a wide-range of programs, from safety assessment and regulatory toxicology, to customized study designs. SNBL USA’s Acute Radiation Syndrome (ARS) program includes countermeasure evaluation resources, from exploratory animal efficacy studies to performing nonclinical GLP pivotal studies under the FDA’s Animal Rule in rodent, minipig and nonhuman primate animal models. This program allows SNBL USA to support drug development efforts for mitigating and treating radiation injury, as well as other important applications for this uniquely suited laboratory.
SNBL USA, Ltd. is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL).